Getting you moving again. Arthrosamid® is a new type of treatment for knee osteoarthritis that offers patients an effective alternative to current therapies. It is a non-biodegradable hydrogel that is injected into the knee to cushion the joint and relieve pain.
Around 1 in every 5 people aged over 45 in England is affected by knee osteoarthritis. But, until recently, there has been little innovation in the range of OA treatments on offer.
Arthrosamid® (a registered trademark of Contura International Ltd.).
Arthrosamid®, developed by Contura International Ltd., is a minimally invasive treatment for knee osteoarthritis. It is administered by trained specialists following established clinical protocols. Our Arthrosamid injection protocol has been developed with over hundreds of patients by Professor Paul Lee, a leading orthopaedic surgeon in Harley Street, London.
Arthrosamid injection is performed under the MSK-K1 mix local anaesthesia under ultrasound guidance with IV anti-biotics cover. The process is smooth and virtually painless.
Arthrosamid® is an intra-articular polycrylamide hydrogel injection for the symptomatic treatment of knee osteoarthritis. Once injected into the inner joint cavity, it restores viscosity within the synovial fluid, improving lubrication and cushioning of the joint. Arthrosamid also integrates into the synovium of the inner joint capsule creating a cushion-like effect.